erythromycin topical

What the FDA Data Shows for erythromycin topical

The FDA label for erythromycin topical (sold under brand names such as Erygel) classifies it as a prescription-only medication in the Topical Antibiotic class. This medicine treats acne vulgaris, a common skin condition. Official labeling lists 5 commonly reported side effects, including Peeling skin, Dry skin, Itching.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.